Bratislava Medical Journal Vol.125, No.4, p.207

Bratislava Medical Journal Vol.125, No.4, p.207–210, 2024

Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.5

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.125, No.4, p.207–210, 2024
Title: Genetic determinants of taxane-induced peripheral neuropathy
Author: Beata MLADOSIEVICOVA, Magdalena NEMCOKOVA JABLONICKA, Lucia TATAYOVA, Michal BERNADIC

Abstract: The efficacy of taxane‑containing regimens has been demonstrated for various cancers, particularly ovarian, endometrial, breast, lung, and prostate cancers. However, extensive taxane-induced toxicities limit their use. Prediction and management of many toxic complications in cancer patients have evolved significantly over the last decade. Peripheral neuropathy is the most typical non-hematological taxane-related complication, and it has a multifactorial pathogenesis. It is often dose-dependent and progressive during therapy and sometimes even after treatment. Unfortunately, the prediction of these common adverse events remains unclear. In the past few years, several polymorphisms of candidate genes with a possible role in the development of this consequence were studied. This minireview aims to highlight the critical yet underappreciated roles of genetic predictors that may increase susceptibility to taxane-induced peripheral neuropathy in cancer patients (Ref. 40).

Keywords: taxanes, paclitaxel, docetaxel, peripheral neuropathy, risk factors, genetic polymorphisms
	Published online: 26-Jan-2024
Year: 2024, Volume: 125, Issue: 4	Page From: 207, Page To: 210
doi:10.4149/BLL_2024_31
	download file

Aepress.sk